Ruxolitinib improved the efficacy of standard-of-care drugs employed in ALL treatment and increased induction rates in synergy with vincristine, dexamethasone, and l-asparaginase in most CRLF2-rearranged Ph-like ALL models. Here, CRLF2 is linked to acute lymphoblastic leukemia.